Vaccine formulations

Details Vaccine formulations Vaccine formulations

2005-03-22

2005-03-22

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S278100, C424S279100

Reexamination Certificate

active

06869607

ABSTRACT:
A vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants is present in the form of a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions. Preferably, it contains substances capable of making the vaccine isotonic, particularly sorbitol.

REFERENCES:
patent: 4147772 (1979-04-01), McAleer et al.
patent: 4338335 (1982-07-01), McAleer et al.
patent: 4849358 (1989-07-01), Chazono et al.
patent: 5776468 (1998-07-01), Hauser et al.
patent: 6258362 (2001-07-01), Loudon et al.
patent: WO 9515768 (1995-06-01), None
patent: WO 9730721 (1997-08-01), None
Yamana et al (Japanese Journal of Cancer & Chemotherapy vol. 27 No. 10, pp 1477-1488), Sep. 2000.*
Abraham, E., “Intranasal Immunization with Bacterial Polysaccharide Containing Liposomes Enhances Antigen-Specific Pulmonary Secretory Antibody Response,”Vaccine 10:461-468 (1992).
Allison, A.C., and Byers, N.E., “Immunological Adjuvants: Desirable Properties and Side-Effects,”Mol. Immunol. 28:279-284 (1991).
Azuma, I., “Synthetic Immunoadjuvants: Application to Non-Specific Host Stimulation and Potentiation of Vaccine Immunogenicity,”Vaccine 10:1000-1006 (1992).
Baker, P.J., et al., “Ability of Monophosphoryl Lipid A to Augment the Antibody Response of Young Mice,”Infect. Immun. 56:3064-3066 (1988).
Barr, I.G., and Mitchell, G.F., “ISCOMs (Immunostimulating Complexes): The First Decade,”Immunol. Cell Biol. 74:8-25 (1996).
Buschle, M., et al., “Transloading of Tumor Antigen-Derived Peptides Into Antigen-Presenting Cells,”Proc. Natl. Acad. Sci. USA 94:3256-3261 (Apr. 1997).
Byars, N.E., et al., “Improvement of Hepatitis B Vaccine by the Use of a New Adjuvant,”Vaccine 9:309-318 (1991).
Elloux, F., et al., “Minimal Structural Requirements for Adjuvant Activity of Bacterial Peptidoglycan Derivatives,”Biochem. Biophys. Res. Commun. 59:1317-1325 (1974).
Gregoriadis, G., “Immunological Adjuvants: A Role for Liposomes,”Immunol. Today 11:89-97 (1990).
Gupta, R.K., and Siber, G.R., “Adjuvants for Human Vaccines-Current Status, Problems and Future Prospects,”Vaccine 13:1263-1276 (1995).
Harrington, D.G., et al., “Adjuvant Effects of Low Dose of a Nuclease-Resistant Derivative of Polyinosinic Acid. Polycytidylic Acid on Antibody Responses of Monkeys to Inactivated Venezuelan Equine Encephalomyelitis Virus Vaccine,”Infect. Immun. 24:160-166 (1979).
Hunter, R., et al., “Adjuvant Activity of Non-Ionic Block Copolymers. IV. Effect of Molecular Weight and Formulation of Titre and Isotype of Antibody,”Vaccine 9:250-256 (1991).
Marx, P.A., et al., “Protection Against Vaginal SIV Transmission with Microencapsulated Vaccine,”Science 28:1323-1327 (1993).
Mbawuike, I.N., et al., “Enhancement of the Protective Efficacy of Inactivated Influenza A Virus Vaccine in Aged Mice by IL-2 Liposomes,”Vaccine 8:347-352 (1990).
Mowat, A.M., and Donachie, A.M., “ISCOM—A Novel Strategy for Mucosal Immunization?”Immunol. Today 12:383-385 (1991).
Newman, M.J., et al., “Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses,”J. Immunol. 148:2357-2362 (1992).
Phillips, N.C. and Emili, A., “Enhancement Antibody Response to Liposome-Associated Protein Antigens: Preferential Stimulation of IgG2a/b Production,”Vaccine 10:151-158 (1992).
Relyveld, E.H., “Preparation and Use of Calcium Phosphate Adsorbed Vaccines,”Develop. Biol. Standard. 65:131-136 (1986).
Ribi, E., “Beneficial Modification of the Endotoxin Molecule,”J. Biol. Response Modifiers 3:1-9 (1984).
Stuart-Harris, C.H., “Adjuvant Influenza Vaccines,”Bulletin of the World health Org. 41:617-621 (1969).
Takahashi, H., et al., “Induction of CD8+ Cytotoxic T Cells By Immunization with Purified HIV-1 Envelope Protein in ISCOMs,”Nature 344:873-875 (1990).
Thaper, M.A., et al., “Secretory Immune Responses in the Mouse Vagina After Parenteral or Intravaginal Immunization with an Immunostimulating Complex (ISCOM),”Vaccine 9:129-133 (1991).
Vogel, F.R., “Immunologic Adjuvants for Modern Vaccine Formulations,”Ann. N.Y. Acad. Sci. 754:153-160 (1995).
Warren, H.S., et al., “Current Status of Immunological Adjuvants,”Ann. Rev. Immunol. 4:369-388 (1986).
Waters, R.V., et al., “Uveitis Induction in the Rabbit by Muramyl Dipeptides,”Infect. Immun. 51:816-825 (1986).

Affiliated with

Also associated with

Rating

Vaccine formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3386043